MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2799-2806

  Rajeshkumar, N V ^a   De Oliveira, Elizabeth ^a   Ottenhof, Niki ^a   Watters, James ^b   Brooks, David ^b,g   Demuth, Tim ^b   Shumway, Stuart D ^b   Mizuarai, Shinji ^c   Hirai, Hiroshi ^c   Maitra, Anirban ^a   Hidalgo, Manuel ^a,d,e,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BANYU PHARMACEUTICAL CO LTD   (Japan)

^d Hospital Madrid Norte Sanchinarro   (Spain)

^e UNIVERSIDAD SAN PABLO CEU   (Spain)

^f Centro Nacional de Investigaciones Oncológicas   (Spain)

^g Generation Health Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; GEMCITABINE; MK 1775; PROTEIN P53; UNCLASSIFIED DRUG; WEE1 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; MITOSIS RATE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG SYNERGISM; FEMALE; GENES, P53; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955492036     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2580     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Li D, Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 2010;16:4313-8.
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
5. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-7.
6. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-8. (Pubitemid 33081637)
7. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
8. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-9.
9. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664-72. (Pubitemid 26414889)
10. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85. (Pubitemid 39050363)
11. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
12. Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, et al. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res 1997;57:1895-902. (Pubitemid 27209718)
13. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
14. Jin P, Gu Y, Morgan DO. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 1996;134:963-70. (Pubitemid 26278221)
15. McGowan CH, Russell P. Cell cycle regulation of human WEE1. Embo J 1995;14:2166-75.
16. Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006;6:292.
17. Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004;3:305-13.
18. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK- 1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
19. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992-3000.
20. Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010;5:186-91.
21. Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 2009;8:34.
22. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33. (Pubitemid 24187791)
23. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61. (Pubitemid 44297818)
24. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
25. Bankert RB, Egilmez NK, Hess SD. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 2001;22:386-93. (Pubitemid 32673645)
26. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009;85:217-21.
27. Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009;15:4138-46.
28. Nallapareddy S, Arcaroli J, Touban B, et al. A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer. J Clin Oncol 2010;28Suppl:abstre14515.
29. Maitra A, Rajeshkumar NV, Rudek M, , et al. Nab®-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models. Proceedings of the 21st AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics ;2009; abstr C246.
30. Von Hoff DD, Ramanathan M, Board M, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study. J Clin Oncol 2009;27Suppl:abstr 4525.
31. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999;18:4047-54. (Pubitemid 29363911)
32. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-9. (Pubitemid 38340288)
33. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997;277:1497-501. (Pubitemid 27449236)
34. Booher RN, Holman PS, Fattaey A. Human Myt1 is a cell cycleregulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 1997;272:22300-6. (Pubitemid 27382865)
35. Parker LL, Sylvestre PJ, Byrnes MJ III, Liu F, Piwnica-Worms H. Identification of a 95-kDa WEE1-like tyrosine kinase in HeLa cells. Proc Natl Acad Sci U S A 1995;92:9638-42.
36. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70:4972-81.
37. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16:376-83.
38. Perona R, Moncho-Amor V, Machado-Pinilla R, Belda-Iniesta C, Sanchez Perez I. Role of CHK2 in cancer development. Clin Transl Oncol 2008;10:538-42.
39. Zenvirt S, Kravchenko-Balasha N, Levitzki A. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents. Oncogene 2010;29:6149-59.
40. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A 2004;101:4419-24. (Pubitemid 38437427)
41. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:216-25. (Pubitemid 38337501)
42. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007;6:104-10. (Pubitemid 46173886)
43. Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Burnet NG, et al. Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. Neuropathol Appl Neurobiol 2005;31:455-66. (Pubitemid 41337780)
44. Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol 2008;1:36-43.